[HTML][HTML] Molnupiravir: A versatile prodrug against SARS-CoV-2 variants
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
[HTML][HTML] Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Vaccine protection from symptomatic SARS-CoV-2 infection has been shown to be strongly
correlated with neutralising antibody titres; however, this has not yet been demonstrated for …
correlated with neutralising antibody titres; however, this has not yet been demonstrated for …
[HTML][HTML] Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
T Zhang, W Tian, S Wei, X Lu, J An, S He… - … Hematology & Oncology, 2023 - Springer
The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge
on public health systems. Despite the measures put in place to contain it, COVID-19 is likely …
on public health systems. Despite the measures put in place to contain it, COVID-19 is likely …
Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA. 2 in Shanghai, February-June 2022
X Chen, X Yan, K Sun, N Zheng, R Sun… - Emerging microbes & …, 2022 - Taylor & Francis
An outbreak of COVID-19 caused by the SARS-CoV-2 Omicron BA. 2 sublineage occurred
in Shanghai, China from February 26 to June 30, 2022. We use official reported data …
in Shanghai, China from February 26 to June 30, 2022. We use official reported data …
[HTML][HTML] Effectiveness of COVID-19 vaccination against SARS-CoV-2 Omicron variant infection and symptoms—China, December 2022–February 2023
The self-reported infection rate, as determined from an online survey, reached its
peak(15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in …
peak(15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in …
Vaccination effects on post-infection outcomes in the Omicron BA. 2 outbreak in Shanghai
Q Wu, H Wang, J Cai, J Ai, Y Li, H Zhang… - Emerging Microbes & …, 2023 - Taylor & Francis
Omicron and its sublineages are currently predominant and have triggered epidemiological
waves of SARS-CoV-2 around the world due to their high transmissibility and strong immune …
waves of SARS-CoV-2 around the world due to their high transmissibility and strong immune …
[HTML][HTML] Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA. 5 infection: a matched cohort study of adult close contacts
Background Although COVID-19 vaccines and their booster regimens protect against
symptomatic infections and severe outcomes, there is limited evidence about their protection …
symptomatic infections and severe outcomes, there is limited evidence about their protection …
[HTML][HTML] Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: Retrospective cohort study
Z Huang, S Xu, J Liu, L Wu, J Qiu, N Wang… - Nature …, 2023 - nature.com
We conducted a matched retrospective cohort study of two cohorts to estimate inactivated
vaccine effectiveness (VE) and its comparative effectiveness of booster dose among older …
vaccine effectiveness (VE) and its comparative effectiveness of booster dose among older …
The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.
1.1. 529) variant is highly transmissible with potential immune escape. Hence, control …
1.1. 529) variant is highly transmissible with potential immune escape. Hence, control …
[HTML][HTML] Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA. 2 infection
F Wang, B Huang, Y Deng, S Zhang, X Liu, L Wang… - BMC medicine, 2023 - Springer
Background Several COVID-19 vaccines are in widespread use in China. Few data exist on
comparative immunogenicity of different COVID-19 vaccines given as booster doses. We …
comparative immunogenicity of different COVID-19 vaccines given as booster doses. We …